Document is current
Any future updates will be listed below
-
Authors
Kim, Yoon Seok https://orcid.org/0000-0003-3332-0652
Gillespie, Shawn M.
Geraghty, Anna C.
Yalçın, Belgin https://orcid.org/0000-0001-9689-9062
Ivec, Alexis English https://orcid.org/0000-0001-8369-3225
Yang, Aerin https://orcid.org/0000-0002-8704-0288
Mancusi, Rebecca
Hysinger, Jared https://orcid.org/0000-0003-2413-6255
Reed, James
Drexler, Richard
Quezada, Michael
Malacon, Karen
Woo, Pamelyn
Byun, Youkyeong Gloria https://orcid.org/0000-0003-4669-0855
Mount, Christopher
Lam, Mable
Pan, Yuan https://orcid.org/0000-0002-9465-8289
Zuchero, J. Bradley
Trotter, Jacqueline
Monje, Michelle https://orcid.org/0000-0002-3547-237X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA165962, R01CA258384, U19CA264504)
Gatsby Charitable Foundation (N/A)
ChadTough Foundation (N/A)
ChadTough Foundation (N/A)
Shoshana Levy Early Career Fellowship
Cancer Prevention and Research Institute of Texas (RR210085)
Deutsche Forschungsgemeinschaft
- License Information
-
More Information
Article History
Received: 3 February 2025
Accepted: 2 July 2026
First Online: 6 August 2026
Ethics
Competing interests: M.M. holds equity in MapLight Therapeutics and Stellaromics, and is on the SAB of S1 Oncology and TippingPoint Biosciences. The remaining authors declare no completing interests.
